174 related articles for article (PubMed ID: 34407044)
41. Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Freyer G; Martinez-Jañez N; Kukielka-Budny B; Ulanska M; Bourgeois H; Muñoz M; Morales S; Calero JB; Cortesi L; Pintér T; Palácová M; Cherciu N; Petru E; Ettl J; de Almeida C; Villanova G; Raymond R; Minh CTT; Rodrigues A; Cazzaniga ME
Breast; 2024 Apr; 74():103681. PubMed ID: 38377732
[TBL] [Abstract][Full Text] [Related]
42. Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.
Petry V; Gagliato DM; Leal AI; Arai RJ; Longo E; Andrade F; Ricci MD; Piato JR; Barroso-Sousa R; Hoff PM; Mano MS
Braz J Med Biol Res; 2015 May; 48(5):479-85. PubMed ID: 25760024
[TBL] [Abstract][Full Text] [Related]
43. Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study.
Pepe FF; Cazzaniga ME; Baroni S; Riva F; Cicchiello F; Capici S; Cogliati V; Maggioni C; Cordani N; Cerrito MG; Malandrin S
BMC Cancer; 2022 Sep; 22(1):956. PubMed ID: 36068484
[TBL] [Abstract][Full Text] [Related]
44. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
Nolè F; Catania C; Sanna G; Imadalou K; Munzone E; Adamoli L; Longerey B; Blanchot G; Goldhirsch A
Ann Oncol; 2006 Feb; 17(2):322-9. PubMed ID: 16303864
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
[TBL] [Abstract][Full Text] [Related]
46. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
Perroud HA; Alasino CM; Rico MJ; Mainetti LE; Queralt F; Pezzotto SM; Rozados VR; Scharovsky OG
Cancer Chemother Pharmacol; 2016 Feb; 77(2):365-74. PubMed ID: 26721701
[TBL] [Abstract][Full Text] [Related]
47. Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted.
Rossi D; Lippe P; Rocchi MBL; Sarti D; Catalano V; Graziano F; Giordani P; Baldelli A; Fedeli SL; Imperatori L; Laici G; Cappelletti C; Tamburrano T; Bracci R; Alessandroni P
In Vivo; 2020; 34(5):2687-2691. PubMed ID: 32871800
[TBL] [Abstract][Full Text] [Related]
48. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Northfelt DW; Allred JB; Liu H; Hobday TJ; Rodacker MW; Lyss AP; Fitch TR; Perez EA;
Am J Clin Oncol; 2014 Apr; 37(2):167-71. PubMed ID: 23211220
[TBL] [Abstract][Full Text] [Related]
49. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
50. Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies.
Petrelli F; Di Cosimo S; Lonati V; Barni S
Clin Breast Cancer; 2016 Oct; 16(5):327-334. PubMed ID: 27282844
[TBL] [Abstract][Full Text] [Related]
51. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Schwartzberg LS; Wang G; Somer BG; Blakely LJ; Wheeler BM; Walker MS; Stepanski EJ; Houts AC
Clin Breast Cancer; 2014 Feb; 14(1):13-9. PubMed ID: 24268206
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.
Cazzaniga ME; Torri V; Riva F; Porcu L; Cicchiello F; Capici S; Cortinovis D; Digiacomo N; Bidoli P
Tumori; 2017 Jan; 103(1):e4-e8. PubMed ID: 27647223
[TBL] [Abstract][Full Text] [Related]
54. Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells.
Parsons HA; Macrae ER; Guo H; Li T; Barry WT; Tayob N; Wulf GM; Isakoff SJ; Krop IE
JCO Precis Oncol; 2021 Nov; 5():896-903. PubMed ID: 34994617
[TBL] [Abstract][Full Text] [Related]
55. Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.
Heudel P; Delaloge S; Parent D; Madranges N; Levy C; Dalenc F; Brain E; Uwer L; D'Hondt V; Augereau P; Mailliez A; Perrin C; Frenel JS; Sablin MP; Mouret-Reynier MA; Vermeulin T; Eymard JC; Petit T; Ferrero JM; Ilie S; Goncalves A; Chenuc G; Robain M; Simon G; Perol D
Anticancer Res; 2020 Jul; 40(7):3905-3913. PubMed ID: 32620631
[TBL] [Abstract][Full Text] [Related]
56. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report.
Aurilio G; Munzone E; Botteri E; Sciandivasci A; Adamoli L; Minchella I; Esposito A; Cullurà D; Curigliano G; Colleoni M; Goldhirsch A; Nolè F
Breast J; 2012 Sep; 18(5):470-4. PubMed ID: 22827581
[TBL] [Abstract][Full Text] [Related]
57. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
[TBL] [Abstract][Full Text] [Related]
58. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
59. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
Platania M; Pasini F; Porcu L; Boeri M; Verderame F; Modena Y; Del Conte A; Nichetti F; Garassino MC; Martinetti A; Sottotetti E; Cavanna L; Vattemi E; Pozzessere D; Bertolini A; Irtelli L; Verri C; Sozzi G; Proto C; Pastorino U; Torri V; Fraccon AP; Spinnato F; Signorelli D; Lo Russo G; Tuzi A; Gallucci R; Cinieri S; Mencoboni M; Antonelli P; Giacomelli L; de Braud F
Lung Cancer; 2019 Jun; 132():17-23. PubMed ID: 31097088
[TBL] [Abstract][Full Text] [Related]
60. [A patient with subcutaneous, lymph node and bone lesions for breast cancer: a progressive response to metronomic oral vinorelbine and capecitabine.].
Ghilardi M
Recenti Prog Med; 2019 Oct; 110(10):490-493. PubMed ID: 31657815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]